<ul>
	<li>Using ESA to target a hemoglobin level of &gt;11 g/dL increase the rate of serious adverse cardiovascular reactions. It should be used with caution in patients with co-existant cardiovascular disease, stroke, seizure etc.</li>
	<li>Control hypertension prior to initiating of and during treatment with it</li>
	<li>Monitoring of patients for the change in seizure frequency or premonitory symptoms.</li>
	<li>If severe anemia and low reticulocyte count develop during the treatment, withhold it and evaluate patients for neutralizing antibodies to erythropoietin</li>
</ul>